Senti to focus on lead blood cancer therapy development, shares rise

Senti Biosciences Holdings

27/01/2023 14:13

** Shares of cancer therapies developer Senti Biosciences
Inc  SNTI.O  up 8.7% at $1.99 premarket  
    ** Co plans to focus resources on its lead cancer therapy
candidate, SENTI-202, and colon cancer therapy candidate
SENTI-401 
    ** SENTI-202 is being tested to treat acute myeloid leukemia
and myelodysplastic syndrome, groups of cancers associated with
the blood and bone marrow -SNTI
    ** Says it does not plan to invest in development of its
liver cancer therapy candidate, SENTI-301A, and is looking for
potential partners to develop it - SNTI 
    ** SNTI expects that the realignment will result in extended
cash runway through at least Q1 2024 
        ** Before realignment efforts, co reported cash and cash
equivalents of $114.9 mln as of September 2022 
    ** Co sees more market opportunity for SENTI-301A in Asia
than in the U.S. 
    ** Stock declined ~81% over the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))